Use of Antiretrovirals for Prevention: PrEP, PEP and ART
July 21, 2010
For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance.
Despite years of prevention efforts, HIV incidence has been inadequately controlled and the HIV/AIDS epidemic remains a global public health crisis. The global response has not been sufficient and the current economic crisis threatens recent gains. Given the gravity of the situation, it is not surprising that the question of how best to use antiretroviral treatment (ART) for prevention has emerged. There is increasing evidence that ART has an effect on both horizontal and vertical HIV transmission, and that it reduces mortality in TB/HIV co-infection. Some experts believe that the implementation of voluntary universal testing programmes, with immediate initiation of ART for individuals who test positive, could significantly reduce HIV incidence. However, expert evaluation and further research are required to assess this novel approach, evaluate its appropriateness and feasibility, and define the requirements for public health decision-making on how to best use ART for prevention. The benefits of antiretroviral drugs can also be extended further into prevention for HIV-negative individuals through antiretroviral pre- and post-exposure prophylaxis. A number of clinical trials to study the effectiveness of pre- exposure prophylaxis are ongoing and results will most likely be available before data from planned field trials on the use of universal test and treat (for HIV-positive individuals). This session will explore the potential synergies of the use of antiretrovirals for HIV-positive and HIV-negative individuals.
Presentations in This Session:
Helen Rees (South Africa)
Potential Role of PrEP/PEP for HIV Prevention in Men Who Have Sex with Men
Impact of Antiretroviral Therapy on HIV Transmission: Results from a Five Year HAART Coverage Expansion in British Columbia, Canada
Modelling Potential Synergies of PrEP and ART for Prevention
ART for Prevention: Opportunities and Challenges
CDC Study Finds Immune System Benefits of Pre-Exposure Prophylaxis for Animals Infected With the Monkey Form of HIV While Taking These Drugs
Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial
This article was provided by Henry J. Kaiser Family Foundation. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)